Barclays PLC Has $6.91 Million Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)

Barclays PLC grew its holdings in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 135.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 396,570 shares of the company's stock after purchasing an additional 227,802 shares during the period. Barclays PLC owned approximately 0.51% of Travere Therapeutics worth $6,908,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of TVTX. Sterling Capital Management LLC raised its stake in shares of Travere Therapeutics by 859.8% in the 4th quarter. Sterling Capital Management LLC now owns 2,361 shares of the company's stock worth $41,000 after buying an additional 2,115 shares in the last quarter. R Squared Ltd bought a new stake in Travere Therapeutics in the fourth quarter worth about $53,000. Summit Investment Advisors Inc. raised its position in Travere Therapeutics by 9.2% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,905 shares of the company's stock worth $138,000 after acquiring an additional 667 shares in the last quarter. Victory Capital Management Inc. acquired a new stake in Travere Therapeutics during the fourth quarter valued at approximately $182,000. Finally, Baader Bank Aktiengesellschaft bought a new stake in shares of Travere Therapeutics during the 4th quarter worth $192,000.

Travere Therapeutics Stock Up 5.6 %

Shares of NASDAQ TVTX traded up $1.03 during trading hours on Monday, hitting $19.36. The stock had a trading volume of 2,369,408 shares, compared to its average volume of 1,520,327. The company has a market capitalization of $1.72 billion, a P/E ratio of -4.72 and a beta of 0.84. The firm's 50-day moving average price is $18.25 and its two-hundred day moving average price is $18.65. The company has a debt-to-equity ratio of 24.96, a quick ratio of 1.68 and a current ratio of 1.71. Travere Therapeutics, Inc. has a 52 week low of $5.24 and a 52 week high of $25.29.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.15). Travere Therapeutics had a negative return on equity of 1,636.87% and a negative net margin of 137.90%. The company had revenue of $74.79 million for the quarter, compared to the consensus estimate of $72.38 million. Analysts anticipate that Travere Therapeutics, Inc. will post -1.4 EPS for the current fiscal year.

Insider Activity at Travere Therapeutics

In related news, SVP William E. Rote sold 5,200 shares of the company's stock in a transaction on Wednesday, February 12th. The shares were sold at an average price of $23.53, for a total transaction of $122,356.00. Following the completion of the transaction, the senior vice president now directly owns 98,519 shares in the company, valued at $2,318,152.07. This represents a 5.01 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CAO Sandra Calvin sold 54,244 shares of the firm's stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $25.00, for a total transaction of $1,356,100.00. Following the completion of the sale, the chief accounting officer now owns 54,410 shares in the company, valued at $1,360,250. This represents a 49.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 156,330 shares of company stock worth $3,507,377. 3.75% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Bank of America boosted their target price on Travere Therapeutics from $29.00 to $31.00 and gave the stock a "buy" rating in a research report on Tuesday, April 1st. Scotiabank reissued an "outperform" rating on shares of Travere Therapeutics in a research report on Friday, April 11th. Canaccord Genuity Group upped their price target on shares of Travere Therapeutics from $45.00 to $47.00 and gave the company a "buy" rating in a research report on Thursday, April 10th. Guggenheim reiterated a "buy" rating and set a $47.00 price objective on shares of Travere Therapeutics in a research report on Monday, April 14th. Finally, JPMorgan Chase & Co. raised their target price on Travere Therapeutics from $42.00 to $44.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $32.08.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.